Von Willebrand Disease

Hematology·MeSH: von Willebrand Diseases

Prevalence

30.0 / 100K

15 drugs in development·6 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(11)

Drug	Company
advate	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
advate	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
antihemophilic factor	SHIRE PLC (SHPGF)
Bypassing Agents	ENANTA PHARMACEUTICALS INC (ENTA)
rfviii	SHIRE PLC (SHPGF)
rvwf	SHIRE PLC (SHPGF)
tak-577	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-577	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
vonicog alfa	SHIRE PLC (SHPGF)
vonvendi	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
vonvendi	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

Phase 2(1)

Drug	Company
ALN-6400	ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Unknown(1)

Drug	Company
vonicog alfa	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

Phase 4(2)

Drug	Company
Emicizumab	ENANTA PHARMACEUTICALS INC (ENTA)
plasma-derived fviii/vwf concentrate	Grifols S.A. (GRFS)

BioSniper tracks 15 drugs in development for Von Willebrand Disease across 6 companies.

There are 2 clinical trials targeting Von Willebrand Disease tracked by BioSniper.

The estimated prevalence of Von Willebrand Disease is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.